Can AI-driven antibiotics succeed in trials?

Today's Big News

Jun 2, 2023

BioNTech’s $200M bet on next-gen Yervoy triggers tumor responses, teeing up phase 3 trial


Facing bankruptcy, RNA-focused Oncorus lays off 'substantially' all its staff


Scientists use AI to find new antibiotics, but can they climb out of the 'valley of death' to the clinic?


Chutes & Ladders—Eikon adds more than a dozen new hires to clinical development unit


'The Top Line': Democratizing access to women's meds , plus this week's headlines

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

BioNTech’s $200M bet on next-gen Yervoy triggers tumor responses, teeing up phase 3 trial

BioNTech has shared an updated look at the data that persuaded it to gamble $200 million on a rival to Bristol Myers Squibb’s Yervoy. The phase 1/2 study linked the anti-CTLA-4 antibody to a 29.6% response rate, offering encouragement to BioNTech and partner OncoC4 as they gear up for a pivotal clinical trial.
12-14
Jun
San Diego, CA
 

Top Stories

Facing bankruptcy, RNA-focused Oncorus lays off 'substantially' all its staff

Oncorus is reducing its head count by 55 people, “representing substantially all" of its workforce.

Scientists use AI to find new antibiotics, but can they climb out of the 'valley of death' to the clinic?

Developing a new antibiotic can take as long as 15 years. But in as little as two, the target bug can develop resistance to it. Scientists are looking to AI to close the gap.

Chutes & Ladders—Eikon adds more than a dozen new hires to clinical development unit

Eikon has brought on more than a dozen new employees to its clinical development team amid a frenzy of deals. Farallon is victorious at Exelixis' annual shareholder meeting. New Bausch & Lomb CEO rejigs executive group with promotions in the business unit.

'The Top Line': Democratizing access to women's meds , plus this week's headlines

This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines.

Clinical trial tech company Slope joins Cancer Moonshot initiative in new public-private partnership

Clinical trial platform company Slope is joining the White House’s Cancer Moonshot initiative as a founding member of the public-private partnership CancerX.

Medtronic finds first technology and innovation chief in former Amazon exec

Where better to find your first-ever chief technology and innovation officer than Big Tech itself? That appears to have been Medtronic’s approach to filling its newest executive position.

ASCO: Novartis pressures Lilly with Kisqali, targeting $3B opportunity in early breast cancer

Novartis has pulled back the curtains on the highly anticipated Kisqali data that previously drove an 8% share-price rally in a single day. As the Swiss pharma aims to bring the CDK4/6 battle with Eli Lilly into earlier treatment of breast cancer, the trial results indicate there's an intense rivalry ahead.

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

In its hunt for the new head of its pharmaceutical systems business—which makes drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

As Sandoz prepares to spin off from Novartis, the company sets sights on new crosstown headquarters

After spinning off from Novartis later this year, generics and biosimilars giant Sandoz plans to move into its new headquarters by the middle of 2024.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Democratizing access to meds, plus the headlines

This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines.

 

Resources

eBook

Strategies to Optimize Clinical Trial Enrollment Timelines

See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps.
Whitepaper

Commercializing Gene Therapies, Part 4 – Market Entry

This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies.
Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events